• Contact Us

  • Pipeline
    NM002 (Nylexa®) for COVID 19 NM002 (Nylexa®) for AMR NM001 (Lynovex®) NP339 for Invasive Fungal Disease NP339 for Respiratory Fungal Disease NP213 (Novexatin®)) NP432

  • Technology

  • Therapeutic Focus

  • About Us
    Board and Management Investors Corporate Social Responsibility

  • News and Events
  • Follow
  • Follow
  • Follow
  • News and Events
  • Therapeutic Focus
  • About Us
    • Board and Management
    • Investors
    • Corporate Social Responsibility
  • Technology
  • Pipeline
    • NM002 (Nylexa®) for COVID19
    • NM002 (Nylexa®) for AMR
    • NM001 (Lynovex®)
    • NP339 for Invasive Fungal Disease
    • NP339 for Respiratory Fungal Disease
    • NP213 (Novexatin®)
    • NP432
  • Contact Us

Appointment of Dr Malcolm Barratt-Johnson to the Board of NovaBiotics

by Paul McIntosh | Nov 10, 2020 | Press Releases

ABERDEEN 10th NOVEMBER 2020. NovaBiotics, the anti-infectives and respiratory therapy Biotechnology Company announces the appointment of Dr Malcolm Barratt-Johnson to its Board as Non-Executive Director. Malcolm is a consultant pharmaceutical physician who has...

The truth about why we need this COVID-19 treatment right now!

by Paul McIntosh | Oct 22, 2020 | Blog Post, Press Releases

By Grant Ellis, Director NovaBiotics Ltd On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will probably never disappear and a vaccine won’t stop it completely.  He also said that ministers and experts...
NovaBiotics secures £1m funding for COVID 19 project

NovaBiotics secures £1m funding for COVID 19 project

by Paul McIntosh | Oct 16, 2020 | Press Releases

NovaBiotics secures £1 million in funding from Innovate UK to support clinical development of Nylexa for COVID-19 Aberdeen, 16 October 2020. NovaBiotics, the clinical stage antimicrobials drug discovery company, announces that it has secured £1 million in funding from...

OBE for NovaBiotics’ CEO in the Queen’s Birthday Honours List

by Paul McIntosh | Oct 12, 2020 | Press Releases, Uncategorized

NovaBiotics’ founder and Chief Executive Officer, Dr Deborah O’Neil FRSE, was amongst those recognised in the Queen’s 2020 Birthday Honours list.  Deborah was made an Officer of the Most Excellent order of the British Empire (OBE) for services to biotechnology,...

“Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy” published today

by Paul McIntosh | Jul 7, 2020 | Press Releases

NovaBiotics are delighted to announce that our latest publication is accessible from today. Teamwork focused on solutions to antimicrobial resistance with our collaborators – Marcelo Der Torossian Torres, University of Pennsylvania Cesar de la Fuente, University...

Recent Posts

  • Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
  • NovaBiotics Attending BIO CEO & Investor Digital Conference
  • Just when we thought things were getting better…..
  • CARE CF 1 oral Lynovex clinical trial data published
  • NovaBiotics in the press

Recent Comments

    NovaBiotics Ltd
    Silverburn Crescent
    Bridge of Don
    Aberdeen
    AB23 8EW, UK

    Tel:+44 (0)1224 711377

    Registered Company
    No. SC272344

    NovaBiotics Inc
    One Boston Place,
    Suite 2600,
    Boston
    MA, 02108

    Tel:+1 866 259 4527

    NovaBiotics
    90 Upper George's Street,
    Dun Laoghaire,
    Co. Dublin,
    A96 R8R9

    Tel:+353 1 2712605

    Registered Company
    No. 642058

    News and Events

    About Us

    Therapeutic Focus

    Technology

    Pipeline

    Contact Us